PomDoctor ^{Filed, US Offering, Nasdaq: POM}

We are a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market measured by the number of contracted doctors in 2022, according to Frost & Sullivan. As of December 31, 2022 and 2023 and June 30, 2024, the cumulative number of contracted doctors stabilized at over 212,000, while the transacting patients increased from around 638,000 as of December 31, 2022 to 654,000 as of December 31, 2023, and further to 683,000 as of June 30, 2024. As of June 30, 2024, our contracted doctors issued approximately 3.04 million prescriptions. With focuses on chronic disease management and pharmaceutical services, our business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Our experience in tackling chronic diseases can be traced back to 2015 when we launch our platform on mobile devices. We strategically chose to focus on this field because chronic diseases last at least one year by definition, and they are hard to cure, prone to complications and require ongoing medical attention. As such, patients with chronic diseases have a great and relatively inelastic demand for frequent and repeat follow-up visits and of drug purchases, which gives a competitive advantage to platforms that are able to maintain long-term, stable doctor-patient relationships.